Can someone here explain the logic of the existing share price of $1.53, Where is the downside the SP now that we have started the Phase 3 trial? We have at least 2 year til the end of phase 3, with ton of good stuff happening, orphan indication trials, regional license deals, new fiancial analyst coverage, peer review articles Does anyone have any idea what the valuation of other biotech companies in a phase 3 trial with this type of magnitude if it is successsful,???? my guess it is far larger that $160 million cad, probably close to $500 million or more, At some point in time the investment community will have to wake up to this major under valuation. Maybe a large article in a major news publication would help things, Tell me again why Russo & partners was hired?